NCT06161688View on ClinicalTrials.gov

Ensitrelvir for Viral Persistence and Inflammation in People Experiencing Long COVID

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 9, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions
Long COVIDPost Acute Sequelae of COVID-19Post-Acute COVID-19
Interventions
DRUG

Ensitrelvir

Those randomized to the experimental arm will receive Ensitrelvir, a protease inhibitor, taken orally for 5 days

OTHER

Placebo

Matching placebo for Ensitrelvir

Trial Locations (1)

94110

UCSF/Zuckerberg San Francisco General Hospital, San Francisco

All Listed Sponsors
collaborator

Shionogi Inc.

INDUSTRY

lead

Timothy Henrich

OTHER